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The FUS-ERG chimeric oncogene has been associated with fatal acute myeloid 
leukemias (AML) carrying the non-random t(16;21) (p11;q22) chromosomal aberration. 
In these leukemias, the presence of the t(16;21) translocation product FUS-ERG is 
associated with a) an increase in blasts with a round or irregular nucleus, basophilic 
cytoplasm, vacuoles and, occasionally, with phagocytosis features; b) the presence of 
micromegakaryocytes; and c) impaired myeloid differentiation with dysplastic 
neutrophils.  Reportedly, ectopic expression of FUS-ERG in murine myeloid precursor 
(L-G) and in human cord blood cells induces changes which, in part, might account for 
the phenotype observed in t(16;21) AML patients.  However, the FUS-ERG-dependent 
mechanisms underlying multilineage hematopoietic differentiation defects are still 
unclear. 
 To understand how FUS-ERG affects granulocytic differentiation, we 
independently generated 32Dcl3-derived myeloid progenitor cell lines expressing HA-
tagged ERG, FUS, and FUS-ERG oncoprotein.  In the presence of the growth factor, IL-
3, all cell lines showed similar proliferation rate without acquiring cytokine-independent 
growth. However, FUS and FUS-ERG, but not ERG, expression decreased the 
susceptibility to apoptosis induced by cytokine-deprivation in a dose-dependent manner.  
Interestingly, viable FUS-ERG-expressing cells (30%) were observed after five days in 
IL-3-deprived culture, whereas no parental cells were viable after 24 hours.  Conversely, 
FUS-ERG-expressing cells showed enhanced proliferation and delayed differentiation 
when cultured in the presence of G-CSF, a growth factor important in granulocytic 
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differentiation.  By contrast, marked apoptosis was observed in G-CSF-treated FUS- and 
ERG-expressing cells.  
To dissect the FUS-ERG-dependent molecular mechanisms underlying altered 
differentiation, we assessed protein levels of G-CSF receptor (G-CSFR) and of the two 
major regulators of myelopoiesis, PU.1 and C/EBPα.  Surprisingly, G-CSFR and 
C/EBPα, but not PU.1, levels were markedly increased in FUS-ERG-expressing cells but 
not in FUS- or ERG-transduced lines.  Moreover, by microarray analysis we found that 
FUS-ERG expression specifically induced a) downregulation of genes either required for 
granulocytic differentiation or inhibiting G-CSF-induced proliferation; b) downregulation 
of pro-apoptotic and growth-suppressor genes and upregulation of positive regulators of 
survival and proliferation; and c) upregulation of genes that either promote 
megakaryocytic differentiation or are markers of differentiation into other hematopoietic 
lineages.  Thus, it appears that FUS-ERG, rather than FUS or ERG overexpression, 
enhances survival and induces proliferation of myeloid progenitors by negatively 













Stem cells are the totipotent cells of the body that are capable of extensive 
proliferation and differentiation (Gilbert, 2003).  Stem cells are induced by the body to 
create all cells of an organism and constantly replenish various organic tissues such as 
blood, skin, and cells of the brain and liver.  In between the stem cell and its terminally 
differentiated progeny cells there is an intermediate population of committed progenitor 
cells that have limited capacity to proliferate and regulated differentiation potentials 
(Watt and Hogan, 2000).  The hematopoietic stem cell (HSC) has the ability of self-
renewal and gives rise to the different types of blood cells (Figure 1).  The adult 
pluripotent hematopoietic stem cells are found in the bone marrow and are responsible 
for generation of blood and lymph cells of the body.  Active bone marrow is found in the 
central cavity of all bones at birth.  However, by young adulthood the vertebrae, hips, 
shoulders, ribs, breastbone, and skull are the only bones of the body that continue to 
actively make blood cells (Beutler and Williams, 2001).  Hematopoiesis is the process by 
which the HSCs proliferate and differentiate to give rise to committed progenitors of the 
blood; lymphoid and myeloid (white cells), and erythroid (red cells) (Figure 2).   











Fig. 1:  Effects of transcription 
factors (green arrows) on 
proliferation and commitment 
of the hematopoietic stem cell 
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These lineage-committed cells terminally differentiate into essential blood cells of the 
mammalian body:  CTLs, plasma, helper T-cells, natural killer (NK) cells, platelets, 
basophils, eosinophils, neutrophils, macrophages, and erythrocytes (Figure 2).  Red cells 
(erythrocytes) and platelets are confined to the blood system whereas the white blood 




There are various factors affecting each step of the lineage pathways called 
hematopoietic growth factors (HGFs).  These factors are also known as cytokines and 
include granulocyte colony-stimulating factor (G-CSF), interleukin-3 (IL-3), granulocyte-
macrophage colony stimulating factor (GM-CSF), CSF-1, macrophage colony 
stimulating factor (M-CSF), stem cell factor (SCF), and tumor necrosis factor (TNF) 
(Gilbert, 2003).  Expression of these regulators is controlled at the transcriptional level 
(Figure 1) by specific molecules (transcription factors) which upon binding DNA, 
activate or repress gene expression.  Transcription is the process where mRNA is 
synthesized from a DNA template.  This process in eukaryotic cells is controlled by the 
RNA polymerase II (Roeder, 2005).  This polymerase binds to specific sequences present 
Fig. 2:  Hematopoiesis. 
IL-3 and G-CSF play a 
pivotal role in myeloid 
differentiation. The 
terminally differentiated 
blood cells are depicted 




at the 5’ end of each gene called promoters and thus initiates RNA synthesis.  Following 
this step is elongation of the polynucleotide at its 3’ end.  Finally, the polymerase reaches 
the termination sequence and ceases transcription.  Following transcription, the newly 
formed messenger RNA (mRNA) leaves the cell nucleus and is translated into protein by 
ribosomes in the cell’s cytoplasm (Rodnina et al., 2005).  The proteins created serve in 
many areas and functions of a cell and many are transcription factors themselves.  These 
factors assist RNA polymerases in transcribing DNA into RNA.  Some of the 
transcription factors are involved in hematopoiesis and include PU.1 and C/EBPα 
(Gilbert, 2003).  The two major HGFs involved in this study are G-CSF and IL-3 and the 






 Fig. 3:  Role of C/EBPα and PU.1 in hematopoietic cell differentiation. (HSC) 
Hematopoietic stem cell; (CMP) common myeloid progenitors; (CLP) common lymphoid 
progenitors; Ikaros, PU.1, GATA-1, NFE2 and C/EBPα are transcription factors. 
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G-CSF is produced by fibroblasts, monocytes, and endothelial cells, and the 
protein primarily stimulates neutrophil differentiation (Figure 2).  G-CSF promotes 
maturation and proliferation of acute myelogenous blast cells in addition to stimulating 
proliferation and maturation of normal common myeloid progenitors (CMP) (Beutler and 
Williams, 2001).  IL-3 is a multi-colony stimulating factor; it stimulates the growth and 
maturation of immature myeloid progenitors into granulocytes, monocytes, erythrocytes, 
megakaryocytes, mast cells, and T-cells (Beutler and Williams, 2001) (Figure 2).   
PU.1 is expressed in the HSCs in addition to the mutipotential progenitors, CMP 
and common lymphoid progenitors (CLP), and has been shown to be a transcription 
factor essential for development of myeloid lineages in hematopoiesis (Scott et al., 1994).  
This factor regulates promoter activity of a multitude of other myeloid genes encoding 
growth factors (i.e. SCL, G-CSF, M-CSF, and GM-CSF).  PU.1 is a member of the ETS 
transcription family and is important in lineage development.  Alterations in this gene 
have been shown to create a loss of development in myeloid and B-Cells (Scott et al., 
1994).  In some cases of acute myeloid leukemia (AML), activity of this factor has been 
shown to be suppressed, which implicates that its inhibition is a crucial step in the 
development of leukemia (Mueller et al., 2002).  Various data collected on PU.1 suggest 
that its degradation increases the self-renewal capacity of erythroid precursors and 
inhibits their differentiation (Tenen et al., 1997).  C/EBPα (CCAAT/enhancer binding 
protein) is a member of a family of leucine zipper transcription factors (Tenen et al., 
1997).  This factor is essential for the induction of genes that regulate granulocytic 
differentiation and expression of cytokine receptors, and is important for normal 
myelopoiesis.  These cytokine receptors include M-CSF, GM-CSF, G-CSF, and IL-3, and 
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genes required for granulocytic differentiation are MPO, LF, Myeloblastin, and others.   
Various studies on C/EBPα have suggested that it is a general inhibitor of cell 
proliferation and, therefore, resembles a tumor suppressor (Watkins et al., 1996).  
C/EBPα is genetically or functionally inactivated in AML and also inhibits the 
transactivation activity of PU.1 (Dahl and Simon, 2003).  Alterations in any step of the 
hematopoietic process (from stem-cell to mature blood cells) can disrupt the normal 
development of these cells and lead to clonal outgrowth of one or more cell lineages 
which can lead to deadly disease such as lymphomas and leukemias (Pereira et al., 1998). 
Lymphomas originate mostly in the lymph node system and are malignancies of 
the B and T cells (Hellman et al., 2001).  Leukemia is a cancer of the blood cells and 
affects the lymphoid or myeloid compartments.  Leukemia is categorized as being either 
chronic or acute.  Chronic leukemias develop in primitive myeloid or lymphoid 
progenitors which retain their ability to function as normal HSCs and continue to 
differentiate normally (Beutler and Williams, 2001).  However, these cells also have the 
tendency to undergo further transformation which leads to inhibited differentiation and 
loss of normal hematopoiesis.  There are four different types of leukemia; chronic 
myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), acute 
lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML) (Figure 4).  This 
study focuses on the last type, AML, one of the most common types of leukemia in the 
Western Hemisphere.  AML is a clonal, malignant disease of the hematopoietic system 
that is characterized by increased proliferation and survival of myeloid immature cells, 
primarily in the bone marrow, and by impaired normal blood cell production (Beutler and 
Williams, 2001).  As the mutant cells gain growth and/or survival advantages over the 
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normal stem cells, its progeny proliferate to form billions of cells.  These processes 
usually result in bone marrow failure, with inhibition of normal hematopoiesis, arrested 
differentiation, neutropenia, anemia, and thrombocytopenia (Beutler and Williams, 
2001).  These place patients at risk for life-threatening infections, end-organ 













Management of AML is complex with only approximately 40% of treated patients 
achieving a long-term complete remission.  Treatment in general consists of induction 
with cytarabine/anthracycline-based chemotherapy regimen (“7+3”) followed by 
consolidation treatments for those patients who achieve complete remission.  The latter 
include high-dose cytarabine-based regimen or myeloblative doses of chemotherapy with 
autologus stem cell support.  For those patients at high risk of relapse; cases with 
Fig. 4:  Types of Leukemia Resulting From Abnormal Hematopoiesis. Microphotographs 
show blood smears form a normal donor and patients with the different types of Leukemia. 
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secondary AML developed from prior hematologic disorders or after receiving 
chemotherapy for unrelated cancers, and for those with cytogenetic or molecular 
aberration predicting early disease recurrence, therapeutic strategies with allogenic stem 
cell transplantation are usually pursued  (Beutler and Williams, 2001).   
 Acute myeloid leukemia is the primary form of leukemia during neonatal years; 
however, it represents only a small number of childhood and adolescent cases.  AML 
incidence increases with age; it accounts for 15-20% of acute leukemias in children and 
around 80% of those in adults (Beutler and Williams, 2001).  AML is only slightly more 
common in males over females and there is minimal difference between incidences in 
African or European descent at all ages.  Per year, there are around 2.3 cases per 100,000 
people at all ages.  Approximately 60% of AML cases are in people at ages of greater 
than 60 years, with a median age of 65-70 (Godwin and Smith, 2003).    
There are numerous predisposing conditions that can lead to the development of 
AML.  These include environmental factors such as exposure to radiation, benzene, and 
alkylating agents.  Some acquired diseases that lead to AML are primary 
thrombocythemia, CML, paroxysmal nocturnal hemoglobinuria, and myeloma (Beutler 
and Williams, 2001).  There are also a number of inherited conditions that increase the 
chance of developing the disease:  Down syndrome, identical sibling with AML, Werner 
syndrome, familial AML, and neurofibromatosis 1 are just a few (Beutler and Williams, 
2001).  Cytogenetic alterations are very common and frequent in the development of 
AML as well (Figure 5).  Some of these mutations include trisomy of chromosomes 8, 4, 
and 13, and deletions of all or part of chromosomes 7 and 5.  In addition to these 
mutations a number of chromosomal translocations have been noted in various leukemias 
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that often cause a rearrangement of a critical region of a protoncogene resulting from 
fusion between two genes.  The fusion genes are often transcription factors that alter 
regulatory sequences that control growth, differentiation, and survival (Hellman et al., 




















One well-known translocation is that of the Philadelphia chromosome in CML 
discovered in 1960.  This is caused by the translocation between the c-ABL gene on 
chromosome 9 and the BCR gene on chromosome 22 which forms the well-known BCR-
ABL fusion gene (reviewed in Calabretta and Perrotti, 2004).  This translocation is also 
seen in approximately 30% of adults suffering from acute lymphoblastic leukemia (Ph1 
ALL).  
In approximately forty to fifty percent of those affected with AML, the somatic 
mutation results from a chromosomal translocation (Beutler and Williams, 2001).  These 
include the translocation (t) between chromosomes 8 and 21 AML1/ETO, t(15;17) PML-
RARα, t(9;11) AF9-MLL, t(7;11) Nup98-HOXA9, and t(16;21)(p11;q22) FUS-ERG 
(reviewed in Marcucci et al., 2005 and in Bloomfield, 2002) (Figure 5).   
Fig. 5:  Genetic and Molecular 
Abnormalities in AML. Genetic 
and or molecular aberrations in 
AML lead to differentiation 




This last translocation between the FUS gene on chromosome 16 and the ERG 
gene on chromosome 21 leads to the production of the FUS-ERG fusion protein (Figure 
6).  The FUS-ERG translocation is very rare and, to date has only been diagnosed in 
approximately 30 patients with AML.  This non-random translocation was also observed 
in one patient with blast crisis of CML and in a few patients with myelodysplastic 
syndrome (MDS) that progressed to AML (Yamamoto et al., 1997).  In the FUS-ERG 
translocation, the RNA-binding domain of FUS is substituted with the DNA-binding 
domain of ERG and the chimeric transcript has been shown to function as a regulator of 
transcription (Yamamoto et al., 1997).  














       
Altered differentiation is a common 








M0, M1, M2, M4, M5, M7
Frequently associated with 







Because AML shows diverse cytomorphological features, it is classified into various 
subtypes (M0, M1, M2, M3, M4, M5, M6 and M7) of the French-American-British 
(FAB) classification (Shimizu et al., 1993).  Occurrence in each subtype is dependent on 
cell type and degree of differentiation.  AML with the t(16;21) translocation shows 
arrested differentiation at different stages (M0, M1, M2, M4, M5, and M7) (Figure 6).  
The M0 stage is characterized by cells that are myeloblastic with minimal differentiation.  
Fig. 6:  t(16;21) Acute Myeloid Leukemia and the FUS-ERG fusion. (left) Generation of the 
chimeric FUS-ERG oncogene and possible mechanisms of leukemogenesis; (right) Clinical 
features of the t(16;21) AML. 
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M1 is characterized by myeloblastic cells without maturation.  M2 cells are myeloblastic 
with maturation.  M3 are promyelocytic, M4 are myelomonocytic, M5 are monocytic, 
M6 are Erythroleukemia, and M7 are megakaryocytic (Krause, 2000).  One group has 
identified 4 different types of mRNA transcripts for FUS-ERG, and although the 
biological implication of the heterogeneity of these transcripts has not been determined, it 
is predicted that these varying transcripts enable the translocation to be implicated in 
these various subtypes of leukemia (Panagopoulos et al., 1995).  The prognosis of 
patients diagnosed with this genetic aberration in AML is very poor and no patients 
achieve complete remission.       
 The FUS/TLS (translocated in liposarcoma) gene encodes an RNA/DNA-binding 
protein and was first discovered as a translocated gene in myxoid liposarcoma (Crozat et 
al., 1993).  In this disease, FUS is fused to the CHOP (c/EBP homologous protein) gene 
(Yang et al., 2000).  The FUS protein serves in transcription regulation and RNA 
metabolism.  It should also be noted that the nuclear RNA-binding protein encoded by 
FUS is homologous in amino-acid sequence to the EWS protein.  It has been shown in a 
subset of Ewing’s Sarcomas that ERG is fused with the EWS gene.  FUS is also closely 
related to TAFII68 (TATA-binding protein-associated factor).  TAFII68, TLS (FUS), and 
EWS interact with RNA polymerase II which implicates that TLS is a transcriptional 
activator (Yang et al., 2000).  In addition, experiments have shown that FUS binds to 
RNA polymerase II through the N-terminal domain and associates with various splicing 
factors via the C-terminal domain (Chansky et al., 2001).  The FUS gene contains a 
highly conserved C-terminus region composed of 80 amino acids called the 
ribonucleoprotein consensus sequence (RNP-CS) (Crozat et al., 1993).  Flanking this is 
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an RNA recognition motif (RRM) and further down from this are Arg-Gly-Gly (RGG) 
repeats and a C2-C2 zinc finger domain (Hackl and Luhrmann, 1996).  It has been 
demonstrated that suppression of FUS expression in myeloid precursor 32Dcl3 cells is 
correlated with upregulation of granulocyte-colony stimulating factor receptor (G-CSFR) 
and downregulation of interleukin-3 receptor (IL-3R) (Perrotti et al., 1998).  In addition, 
G-CSF-stimulated differentiation was seen to be accelerated in FUS-knock-down 
myeloid cells (Perrotti et al., 2000).  The FUS gene has also been found to be upregulated 
in CML-BC (blast crisis) (Perrotti et al., 1998).      
ERG (ets-related gene) is a member of the ETS gene superfamily which consists 
of a number of genes that encode for transcriptional regulators in a variety of 
developmental mechanisms.  These transcription factors play important roles in cell 
development, proliferation, differentiation, apoptosis, tissue remodeling, and deregulation 
of ETS genes leads to malignant transformation of cells (Oikawa, 2004).  ETS proteins 
bind to ETS-binding sequences of DNA through a uniquely conserved winged helix-turn-
helix motif (Donaldson et al., 1994).  Two of these genes are ETS-1 and ETS-2, both of 
which have been implicated in oncogenesis and cellular transformation when 
overexpressed (Myers et al., 2005).  The ERG gene encodes for five proteins; Erg-1, Erg-
2, Ergp55, Ergp49, and Ergp38 (Carrere et al., 1998).  ERG overexpression decreases 
apoptosis of serum-deprived NIH3T3 cells (Yi et al., 1997).  Furthermore,  it has been 
shown that ERG overexpression in mouse fibroblast NIH3T3 cell lines alters 
morphological features, allows cells to grow in low and serum-free media, and gives rise 
to colonies in soft agar (Hart et al., 1995), thus, ERG may contribute to oncogenesis.  In 
addition, mice injected with ERG-expressing cells ectopically developed tumors, which 
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suggests that ERG overexpression may contribute to tumor transformation (Ichikawa et 
al., 1999).  In addition to ERG, the APP (β-amyloid precursor protein)  gene is located on 
chromosome 21 in close proximity to ERG and ETS-2 transcription factor and has been 
shown to be overexpressed in AML (Baldus et al., 2004).  This protein is also associated 
with Down Syndrome and has previously been implicated in Alzheimer’s disease 
(Wolvetang et al., 2003). 
 FUS-ERG has been shown to arrest erythroid and alter myeloid differentiation 
and to increase proliferation and self-renewal capacity of human myeloid progenitors 
(Pereira et al., 1998).  The translocation increases the number of blast cells which exhibit 
the following characteristics:  round or irregular nucleus, basophilic cytoplasm, vacuoles, 
and phagocytic features.  The presence of micromegakaryocytes is also observed.  In 
addition, the chimeric protein has been demonstrated to induce anchorage-independent 
growth in 3T3 fibroblasts and to block neutrophilic differentiation of myeloid L-G cells 
(Ichikawa et al., 1999).  It seems that FUS is required for FUS-ERG-dependent 
suppression of differentiation.  This fusion protein has also been suggested to cause 
cellular abnormalities by interfering with FUS-mediated RNA splicing by serine-arginine 
proteins (Yang et al., 2000).  While FUS-ERG is known to be associated with AML, the 
mechanism by which the fusion protein acts is still unclear.  Thus, the goal of this study 
is to investigate whether the effects of the translocated fusion gene, FUS-ERG, in acute 
myeloid leukemia cells depend on interference with FUS RNA regulatory activity or with 








1. Effect of ERG and FUS-ERG on proliferation and survival of myeloid progenitors.  
To assess the effect of FUS-ERG expression on proliferation and survival of 
myeloid progenitor cells, the IL-3-dependent 32Dcl3 mouse myeloid precursors were 
infected with neomycin- or green fluorescent protein (GFP)-containing bicistronic 
retroviruses carrying the hemagglutinin (HA)-tagged FUS-ERG, ERG, and FUS cDNAs 
(Figure 7).  After antibiotic (G418)-mediated selection or FACS-mediated sorting of GFP 
positive cells, the newly established cell lines were used in proliferation and survival 
assays.   
 
To assess the effects of ERG and FUS-ERG on proliferation and survival of myeloid 
progenitors, parental 32Dcl3, FUS-, ERG-, and FUS-ERG-expressing cells were grown 
in the presence of IL-3 (Figure 8) and absence of IL-3 for 0 to 36 hours (Figure 9).  As 
shown, proliferation of the IL-3-growing cell lines was identical to that of parental cells 
(Figure 8).  While parental 32Dcl3 and 32D-ERG cells died by 24 hours of culture in the 
Fig. 7:  Expression of FUS, ERG and FUS-ERG 
in myeloid precursors. Anti-HA Western blots 
show ectopic HA-tagged FUS, ERG and FUS-
ERG proteins in mouse myeloid 32Dcl3 cells. 




absence of IL-3 (Figures 9), 32D-FUS-ERG cells were less prone to undergo apoptosis 
induced by IL-3 deprivation (Figure 9). 
   
In fact, 30% of FUS-ERG cells were still alive after five days in culture with absence of 
IL-3 (not shown).  Interestingly, the 32D-FUS cells also behaved as the FUS-ERG cells 
and exhibited delayed apoptosis in absence of IL-3 (Figures 9).  These results suggest 
that the fusion protein gains an oncogenic function by circumventing cytokine-generated 
survival signals.  However, FUS-ERG cells failed to become completely growth factor-
independent and were all apoptotic within a week of culture (not shown).  
 
 
Fig. 8.  Effects of ERG, FUS, and FUS-
ERG on IL-3-dependent proliferation of 
myeloid 32Dcl3 cells.  Growth of parental, 
FUS-ERG-, ERG- and FUS-expressing 
32Dcl3 cells in IL-3-supplemented 
cultures.  Viable cells were counted over a 
72 hour time period by trypan-blue 
exclusion test. Lines in the graph represent 
Mean±SD. Representative of three 
different experiments with similar results.   
Fig. 9.  Effects of IL-3 deprivation on 
survival of parental, ERG-, FUS-, and 
FUS-ERG-expressing myeloid 32Dcl3 
cells.  Graph shows survival of parental 
32Dcl3 and derivative cell lines upon IL-3 
starvation. Viable cells were assessed by 
trypan-blue exclusion test. Representative 




2. Effect of ERG and FUS-ERG expression on G-CSF-driven granulocytic 
differentiation of myeloid progenitors. 
Because dysplastic myeloid maturation is a characteristic feature of patient-
derived t(16;21) AML cells (Hiyoshi et al., 1995), and ectopic FUS expression impairs 
G-CSF-driven granulocytic differentiation and induces apoptosis of G-CSF-cultured 
myeloid precursors (Perrotti et al., 1998; Perrotti et al., 2000), we investigated the effects 
of FUS-ERG and ERG overexpression to determine whether altered differentiation in 
t(16;21) AML depends on FUS-ERG expression, and whether ERG overexpression might 
account for those effects.  Thus, growth and morphology were monitored in parental, low 
and high ERG-, and FUS-ERG-expressing 32Dcl3 cells exposed to G-CSF for 7 to 9 
days, (10% of U87MG conditioned medium as source of crude G-CSF).  Parental 32Dcl3 
cells ceased to proliferate after 4 days of culture in the presence of G-CSF (Figure 10) 
and underwent complete granulocytic differentiation by day 7 (Figure 11).  
 
By contrast, G-CSF-treated FUS-ERG-expressing cells showed enhanced proliferation 
(Figure 10) and delayed differentiation, as mitotic cells, vacuolated myeloblasts, cells at 
intermediate stages of maturation (myelocytes and metamyelocytes) and cells with 
Fig. 10.  Effect of ERG and FUS-ERG on 
G-CSF-driven proliferation of myeloid 
32Dcl3 cells.  Graph shows growth of 
parental 32Dcl3 and derivative cell lines 
upon exposure to G-CSF. Viable cells were 
assessed by trypan-blue exclusion test. 
Representative of three independent 
experiments with similar results. 
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segmented nuclei (polymorphonuclear cells; neutrophils) were evident after 9 days of 
culture in G-CSF-containing medium (Figure 11).  Thus, altered myeloid differentiation 





Unexpectedly, 32D-ERG-expressing cells, like FUS-expressing 32Dcl3 myeloid 
progenitor cells (Perrotti et al., 1998), did not show enhanced proliferation or 
differentiation in response to G-CSF but underwent apoptosis by day 5-6 (Figures 10 and 
11).  Interestingly, in parental 32Dcl3 cells, levels of endogenous ERG progressively 
decrease during G-CSF-induced neutrophilic maturation (Figure 12), suggesting that 
downregulation of ERG expression is required for differentiation.     
Fig. 11.  Effect of ERG and FUS-ERG on G-CSF-driven granulocytic differentiation of myeloid 32Dcl3 
cells.  Microphotographs show May-Grunwald/Giemsa stained cytospin of parental, ERG-, and FUS-ERG-
expressing 32Dcl3 cells exposed for the indicated time to G-CSF.  Representative of three independent 




Thus, these results suggest that overexpression of ERG or FUS alone does not account 
for the effect of FUS-ERG on differentiation of myeloid cells, which is most likely the 
result of either interference with ERG transcriptional activity or FUS-dependent 
regulation of mRNA transcription and splicing.  Alternatively, the effects of FUS-ERG 
on myeloid differentiation might be a specific effect of the fusion protein itself. 
 
 
3.   Effect of FUS, ERG, and FUS-ERG expression on levels of transcription factors 
important for myeloid differentiation.  
To dissect the FUS-ERG-dependent molecular mechanisms underlying altered 
differentiation, we assessed the effects of FUS, ERG, and FUS-ERG expression on the 
protein levels of the transcription factors PU.1, C/EBPα, and C/EBPε that, as extensively 
reported (reviewed in Tenen, 2003), are essential for differentiation of CMP cells toward 
the more committed granulocytic precursors, initial maturation of myeloblasts, and 
terminal maturation of myelocytes into neutrophilic cells, respectively.   
In 32Dcl3 cells, overexpression of FUS suppresses C/EBPα expression (Figure 
13, lane 2). Consistent with this finding, expression of a FUS mutant with dominant 
negative activity (S256A FUS), but not of the dominant active S256D FUS mutant 
(Perrotti et al., 2000), rescued C/EBPα expression back to normal levels (Figure 13, lanes 
Fig. 12.  Modulation of ERG expression during G-
CSF-induced granulocytic differentiation of myeloid 
32Dcl3 cells.  Western blot shows levels of ERG and 
GRB2 (loading control) in 32Dcl3 cells exposed for 0 to 
9 days to G-CSF. 
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1, 3, and 4), suggesting that altered differentiation of FUS-ERG cells might depend on 
the effect of the FUS portion of FUS-ERG on C/EBPα expression.  
 
In agreement with this hypothesis, C/EBPα levels were clearly higher in three single 
clones of FUS-ERG-expressing cells than in parental 32Dcl3 cells (Figure 14, left panel).  
Furthermore, upregulation of C/EBPα by FUS-ERG appears to be dependent on the 
levels of the fusion protein itself, as C/EBPα protein levels are higher in 32Dcl3 cells 
highly expressing FUS-ERG than in a 32Dcl3 cell line expressing lower levels of FUS-











Fig. 14.  Effect of FUS-ERG expression on C/EBPα, C/EBPε, PU.1, and G-CSFR protein levels in 
32Dcl3 myeloid progenitor cells.  Western blots show expression of C/EBPα, C/EBPε, PU.1, and G-
CSFR in parental and in high (32D-FE1-3) and low (32D-FEP) FUS-ERG-expressing 32Dcl3 cells. 
Levels of the ectopic HA-FUS-ERG are depicted in the 4th row (left panel) and in the 3rd row (left 
panel).  Levels of GRB2 were monitored as control for equal loading. 
Fig. 13.  Effect of FUS expression on C/EBPα 
protein levels in 32Dcl3 myeloid progenitor cells.  
Western blots show expression of C/EBPα in 
32Dcl3 cells ectopically expressing wild type FUS 
(lane 2) or the dominant negative S256A or the 
dominant active S256D FUS mutant (Perrotti et al., 
2000).  Levels of HSP90 were monitored as control 
for equal loading. 
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Consistent with this finding, levels of the C/EBPα-regulated G-CSFR were also increased 
in FUS-ERG-expressing 32Dcl3 myeloid progenitors (Figure 14, left panel).  By contrast, 
levels of C/EBPε and PU.1 were not affected by FUS-ERG expression (Figure 14), 
suggesting that PU.1 and C/EBPε transcription factors are not targets of FUS-ERG pro-
leukemogenic activity.   
In 32Dcl3 myeloid precursors ectopically expressing low (32D-M12) or high 
(32D-M4) levels of ERG protein, C/EBPα expression was similar to that of parental 
32Dcl3 cells (Figure 15, lanes 3 and 4). 
 
However, expression and activity of other molecules involved in the regulation of 
myeloid differentiation were also aberrantly regulated by ERG and/or FUS-ERG 
overexpression.  Interestingly, expression of some of these factors appears to be regulated 
at the transcriptional level because they have also been detected by microarray performed 
on FUS, ERG, and FUS-ERG-expressing cells (see section 5 of results).  For example, 
levels of Myb, a transcription factor essential for proliferation and initial maturation of 
immature myeloid cells (Gonda, 1998), was markedly inhibited by FUS-ERG expression 
Fig. 15.  Effect of ERG and FUS-
ERG expression on regulators of 
myeloid differentiation and on APP 
levels. Western blots show expression 
of active STAT3, APP, 
C/EBPα, active MAPK ERK1/2, and 
Myb in 32Dcl3 cells ectopically 
expressing FUS-ERG (32D-FE3) (lane 
2), High ERG (lane 3) and low ERG 
(lane 4) levels. Level of ectopic HA-
tagged FUS-ERG and ERG are shown 
in the 6th panel. Levels of GRB2 were 
monitored as control for equal loading. 
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(Figure 15).  Moreover, both FUS-ERG and ERG expression enhanced activity of the 
signal transducer and activator of transcription 3 (STAT3), a G-CSF-induced 
transcription factor frequently activated in AML that augments proliferation and C/EBPα 
differentiation-inducing activity (Benekli et al., 2003; Coffer et al., 2000; Numata et al., 
2005; McLemore et al., 2001; Lai et al., 2003).  Similarly, activity of the mitogen 
activated protein kinase ERK1/2 was induced by FUS/ERG overexpression (Figure 15).  
Of note, it has been shown that ERK1/2 activity inhibits myeloid differentiation upon 
phosphorylation of C/EBPα on serine 21 (Ross et al., 2004). 
 
4.   Effect of ERG and FUS-ERG expression on APP levels and cellular localization in 
myeloid progenitor 32Dcl3 cells.  
Changes in amyloid precursor protein (APP) expression were investigated 
because it has been recently shown that its levels are increased in AML and correlated 
with that of ERG (Baldus et al., 2004).  As shown, APP expression is strongly enhanced 
in ERG and FUS-ERG expressing cells (Figure 15).  However, APP expression 
dramatically decreases upon G-CSF treatment of parental and FUS-ERG-expressing 
32Dcl3 cells (Figure 16), suggesting that either high APP levels might be non-compatible 
with myeloid differentiation or APP expression is associated with growth, and levels 





The effect of ERG and FUS-ERG is not only evident on APP expression; in fact, by 
confocal microscopy performed on anti-APP antibody-stained cytospinned cells, we 
found APP primarily localized in the cytoplasm of parental 32Dcl3 cells whereas it was 
relocated in the nucleus in 32D-FUS-ERG and 32D-ERG cells (Figure 17).  These data 
suggest that overexpression of ERG and, consequently, increased nuclear APP levels may 





Fig. 16.  Effect of IL-3 and G-CSF 
treatment on APP expression in 
parental and FUS-ERG-expressing 
32Dcl3 cells. Western blots show 
expression of APP in 32Dcl3 and 
FUS-ERG (32D-FE3) maintained in 
culture in the presence of IL-3 (lanes 1 
and 2) or induced to differentiate for 3 
days with G-CSF (lanes 3 and 4). 
Levels of GRB2 were monitored as 
control for equal loading. 
32D-ERG 32D-FUS-ERG 32Dcl3 
Fig. 17.  APP localization in parental, FUS-ERG-, and ERG-expressing 32Dcl3 cells.  Confocal 
microscopy on anti-APP-stained cells.  Insets depict magnified areas.  
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5.  Global effect of ERG and FUS-ERG on the transcription profile of myeloid 
progenitor 32Dcl3 cells. 
To determine the effect of ERG and FUS-ERG on gene expression, 
oligonucleotide array analysis was performed using total RNA obtained from the IL-3-
cultured parental, FUS-ERG- (FE3 and FEP), and ERG- (M4 and M12), and FUS-
expressing 32Dcl3 cells.  Interrogation of Affymetrix Microarray revealed a discrete 
number of genes regulated by ERG, and/or FUS-ERG (Table 1).  For example, cell lines 
expressing FUS-ERG had upregulated genes required for survival and proliferation, 
megakaryocytic differentiation and lymphocytic markers, whereas genes required for G-














Table 1.  Genes regulated by ERG, FUS-ERG, and FUS in relation to parental 32Dcl3 cells. 
             
Gene Title                                                                  Gene Symbol                                 Folda 
                                                      ERG       FUS-ERG       FUS 
neuroblastoma myc-related oncogene 1                     N-myc 1  6.08    2.0       13.98 
transglutaminase 2, C polypeptide                      Tgm2                                   13.93       10.18 
interleukin 2 receptor, alpha chain                       Il2ra                                     3.80         9.30 
CCAAT/enhancer binding protein (C/EBP), alpha                     C/EBPα                           -1.91 
homeo box C8         Hoxc8   1.89 
v-maf musculoaponeurotic fibrosarcoma                      Mafb                 -1.51 
   oncogene family, protein B (avian) 
MAD homolog 4 interacting transcription                       Mitc1                 -1.52 
    coactivator 1 
frizzled-related protein         Frzb                 -1.62 
gasdermin         Gsdm                 -1.65 
colony stimulating factor 3 receptor (granulocyte)                    Csf3r(G-CSFR)       2.75 
nuclear factor of kappa light chain gene                       Nfkb1                       1.80              5.27 
    enhancer in B-cells 1 
Von Willebrand factor homolog                       Vwf                                      6.80 
myeloproliferative leukemia virus oncogene                      Mpl                       2.00 
myeloblastosis oncogene                        Myb                     -1.60 
myeloperoxidase                        Mpo                                    -2.10 
helix-loop-helix Id2           Id2     -2.50 
wild-type p53-induced gene 1                       Wig1                                    -2.10 
BCL2/adenovirus E1B 19 kDa-interacting                    Bnip3                     -2.70 
   protein 1, NIP3 
cytokine inducible SH2-containing protein 3  cis3/SOCS3     -2.0 
complement component 3                        C3                                     1.66              3.05 
S100 calcium binding protein A8 (calgranulin A)                   S100a8                 1.54             6.22 
glycoprotein 49 B                      Gp49b                 1.53    6.61             3.54 
colony stimulating factor 2 receptor, beta 2,                    Csf2rb2       1.93 
   low-affinity (granulocyte-macrophage) 
amyloid beta precursor protein (cytoplasmic tail)                     Appbp2           -1.50 
   binding protein 2 
             




Interestingly, a gene upregulated by FUS-ERG is the G-CSFR which, as we previously 
showed, is overexpressed in FUS-ERG cells in a dose-dependent manner (Figure 14). 
Similarly, other transcription factors like NF-Kb were upregulated by FUS-ERG.  Indeed, 
anti-p65 NFkB western blot shows that NFkB is a true transcriptional target of FUS-ERG 
(Figure 18).  
 
Genes encoding markers of differentiation of different hematopoietic lineages (Mpl, vWf, 
and IL-2Rα) were also upregulated in FUS-ERG cells, consistent with the observation 
that leukemic cells from t(16;21) AML patients present lymphoid and megakaryocytic 
markers of differentiation (Hiyoshi et al., 1995).  
Some downregulated genes in FUS-ERG-expressing cells included myeloblastin, 
myeloperoxidase (MPO), and lactoferrin (LF), three factors whose activity is required  
for differentiation into mature granulocytes (Berliner et al., 1995; Lutz et al., 2001).  The 
levels of the mRNAs encoding the proto-oncogene Myb, the inhibitor of differentiation 
Id2 and the suppressor of cytokine signaling 3 (SOCS3), all of which are inhibitors of G-
CSF induced differentiation (Yanagisawa et al., 1991; Cooper and Newburger, 1998; 
Croker et al., 2004), were downregulated in FUS-ERG-expressing cells as well.  
Consistent with this data we have already shown that Myb protein is downregulated by 
FUS-ERG expression (Figure 15).  Other genes transcriptionally downregulated by FUS-
Fig. 18.  Effect of FUS-ERG on NFkB expression. 
Western blot show expression of NFkB in parental, 
high (lane 2) and low (lane 3) FUS-ERG-expressing 
cell lines. Levels of GRB2 were monitored as 
control for equal loading. 
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ERG were the pro-apoptotic and growth suppressors Wig-1 and BNIP-3 (Hellborg et al., 
2001; reviewed in Zhang et al., 2003).   
The proto-oncogene N-myc 1 was found among those genes upregulated in 
microarrays of ERG and FUS-ERG overexpressing 32Dcl3 cells.  Anti-N-Myc 
immunoblotting confirmed the microarray data; in fact, levels of N-Myc protein were 
markedly increased is 32Dcl3 cells ectopically expressing ERG and FUS-ERG (Figure 
19).  





Another gene upregulated in ERG-expressing cells was HOXC8, a transcription 
factor belonging to the homeobox family whose enhanced expression correlates with loss 
of differentiation (Waltregny et al., 2002).  Other genes downregulated in ERG-
expressing cells include: MafB (v-maf) which is a leucine zipper transcription factor; the 
MAD homolog 4 interacting transcriptional coactivator Mitc1; gasdermin (GSDM), a 
protein whose expression is suppressed in Gastro-Intestinal cancer (Saeki et al., 2000); 
and Frzb, an inhibitor of the wnt signaling pathway whose loss is apparently associated 





Fig. 19.  Effect of FUS-ERG, ERG, and FUS 
overexpression on N-Myc expression. Western blot 
shows expression of N-Myc protein in parental 
(lane 1), FUS-ERG (lane 2), ERG (lane 3) and FUS 
(lane 4)-expressing cell lines.  Levels of GRB2 were 






In the rare and fatal AML with the recurrent t(16;21) translocation, leukemic cells 
show enhanced proliferation and dysplastic myeloid differentiation (Hiyoshi et al., 1995); 
in fact, the t(16;21) translocation was found not associated to a specific FAB phenotype 
(Kong et al., 1997).  Although few studies indicate that FUS(TLS)-ERG, the product of 
the t(16;21) translocation (Panagopoulos et al., 1994), plays a pivotal role in promoting 
leukemogenesis (Pereira et al., 1998; Ichikawa et al., 1999), there is no formal evidence 
showing that it can transform hematopoietic stem cells or committed myeloid progenitors 
and induce leukemia in mice.  
Despite it being shown that the FUS-ERG fusion protein has potent 
transcriptional transactivation activity (Prasad et al., 1994), the mechanisms whereby it 
alters the phenotype and, perhaps, induces leukemic transformation of myeloid 
progenitors is still largely unknown.  Here, we reported that FUS-ERG expression 
decrease susceptibility to apoptosis induced by cytokine deprivation and enhances G-
CSF-driven proliferation of mouse myeloid progenitor 32Dcl3 cells.  Furthermore, we 
also provided evidence showing that increased survival was a characteristic shared 
between FUS-ERG and FUS but not ERG overexpressing cells, whereas the G-CSF-
induced proliferative advantage was a specific feature of FUS-ERG cells.  Aberrant G-
CSF-dependent proliferation was also accompanied by delayed granulocytic 
differentiation of FUS-ERG cells.  Consistent with this observation, it has been reported 
that expression of FUS-ERG in primary CD34+ cord blood cells markedly enhances self 
renewal and inhibits erythroid development (Pereira et al., 1998).  Seemingly, the patient-
derived myeloblastic YNH1 cells, which carry the t(16;21) translocation and express the 
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FUS-ERG fusion protein, do not undergo granulocytic differentiation but continuously 
proliferate if exposed to G-CSF (Yamamoto et al., 1997).  Although the FUS-ERG-
induced phenotypic changes might resemble those of leukemic cells, FUS-ERG 
expression did not confer growth factor independence to 32Dcl3 myeloid progenitors.  
Similarly, proliferation of L-G myeloid precursors transduced with a FUS-ERG-
expressing construct remained dependent on the exogenous support of cytokines 
(Ichikawa et al., 1999).  
Although FUS-ERG expression may be not sufficient to fully transform cells, 
altered differentiation of FUS-ERG-expressing myeloid progenitor 32Dcl3 cells seems to 
be a direct consequence of FUS-ERG expression.  In fact, the presence of vacuolated 
blast cells with irregular nuclei, frequent mitosis, cells arrested at different stages of 
maturation, and expression of lymphoid and megakaryocytic markers in myeloid 32D-
FUS-ERG cells exposed for 9 days to G-CSF has also been observed in specimens from 
t(16;21) AML patients (Hiyoshi et al., 1995).  
Because differentiation arrest is a common feature of acute leukemias, and   
genetic or functional inactivation of C/EBPα, the major regulator of granulocytic 
differentiation (Zhang et al., 1997), has been found associated to myeloid leukemias with 
normal cytogenetic or carrying specific chromosomal abnormalities (Perrotti et al., 2004), 
we asked whether the aberrant differentiation of FUS-ERG-expressing cells results from 
loss of C/EBPα function.  Unexpectedly, C/EBPα expression was upregulated in FUS-
ERG-expressing cells, downregulated in FUS-expressing cells, and unaffected in ERG-
expressing cells.  Moreover, increased C/EBPα expression appears to correlate with 
increased C/EBPα transcriptional activity, as levels of the C/EBPα target G-CSFR 
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(Zhang et al., 1998) were also upregulated.  Increased expression of the G-CSF receptor 
(G-CSFR) may explain the enhanced survival of FUS-ERG cells cultured in the presence 
of G-CSF; however, the presence of high levels of C/EBPα argue against this simple 
interpretation.  In fact, C/EBPα is not only an inducer of differentiation but also a strong 
growth suppressor (Friedman, 2002).  Since G-CSF can amplify its mitogenic signals by 
inducing the expression of its own receptor (Steinman and Tweardy, 1994) and induce 
granulocytic differentiation in a C/EBPα-independent manner (Collins et al., 2001), it is 
possible that increased C/EBPα expression reflects a mechanism that tries to compensate 
the growth advantage induced by the effects of G-CSF through STAT3 signaling.  
Indeed, we have shown that STAT3 activity is enhanced in FUS-ERG-expressing 
myeloid cells.  In this scenario, we must expect that FUS-ERG activates pathways 
leading to post-translational inactivation of C/EBPα that, in turn, becomes unable to 
induce G1/S arrest and differentiation.  In line with this hypothesis, we found that FUS-
ERG augments MAPK ERK1/2 activity that, as previously reported, inhibits C/EBPα 
transcriptional and growth suppressive functions upon phosphorylation of C/EBPα serine 
21 (Ross et al., 2004).  
Although altered differentiation of FUS-ERG-expressing cells might, in part, 
depend on functional inactivation of C/EBPα, the expression profile of 32D-FUS-ERG 
cells indicate that upregulation of growth-promoting genes together with downregulation 
of genes with pro-apoptotic, growth suppressive, and differentiation inhibitory function 
might account for enhanced proliferation and dysplastic differentiation of committed 
myeloid progenitor cells.  
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Interestingly, we also found the amyloid precursor protein (APP) to be 
upregulated by FUS-ERG and ERG expression.  Although we still do not understand the 
function of APP in myelopoiesis and in leukemia, it appears clear that it might have an 
important role in these processes because of the ability of FUS-ERG and ERG to induce 
APP expression and relocation into the nuclear compartment.  Note that it has been 
recently reported that increased APP and ERG expression correlate with poor prognosis 
of AML patients with chromosome 21 abnormalities (Baldus et al., 2004).  Interestingly, 
APP was one of the few genes whose expression was regulated in a similar manner by 
both ERG and FUS-ERG.  Moreover, we did not find factors (with the exception of 
C/EBPα) which were similarly or antagonistically modulated by FUS and FUS-ERG 
expression, suggesting that FUS-ERG neither represents a more powerful transcription 
factor enhancing expression of ERG-target genes, nor a protein that strongly interferes 
with FUS activities. 
In summary, we favor the hypothesis that FUS-ERG predisposes myeloid cells to 











Loss of tumor suppressors




Fig. 20.  Role of FUS-ERG in 
leukemogenesis. FUS-ERG may 
alter differentiation of myeloid 
progenitors and, eventually, 
predispose them to become 
leukemic upon oncogenic activation 




Indeed, the t(16;21) translocation was also found in patients with myelodysplastic 
syndrome (MDS) that subsequently developed AML (Hiyoshi et al., 1995).  However, we 
cannot exclude the possibility that FUS-ERG might be capable of transforming primary 
hematopoietic stem cells and induce a series of phenotypic changes characteristic of the 
t(16;21) AML.  Additional studies aimed at investigating the molecular mechanism 
whereby FUS-ERG regulates gene expression will provide further insight into the role of 
FUS-ERG in leukemogenesis.  Specifically, experiments aimed at assessing the effects of 
FUS-ERG and ERG on proliferation, survival, and differentiation of primary CD34+ 
human bone marrow cells and at determining whether FUS-ERG expression in normal 
marrow cells induces leukemia in immunocompromised NOD/SCID mice might unveil 
new insights into the molecular mechanisms responsible for differentiation arrest of acute 
myeloid leukemias cells.  A better understanding of the complexity of these mechanisms 
might help the identification of novel therapeutic drugs aimed at restoring the normal 





MATERIALS AND METHODS 
 
Cell Lines  
The murine IL-3-dependent 32Dcl3 myeloid precursor cells and derivatives were 
maintained in culture in Iscove’s modified Dulbecco medium (IMDM) supplemented 
with 10% heat-inactivated FBS (Gibco, BR, Gaithersburg, MD), 2mM L-Glutamine 
(Gibco, BR, Gaithersburg, MD), 1% penicillin/streptomycin (Gibco, BR, Gaithersburg, 
MD), and 10% WEHI-conditioned medium as a source of IL-3.  The 32Dcl3 HA-FUS-, 
HA-ERG-, and HA-FUS-ERG-expressing cells were generated by retroviral infection as 
previously described (Perrotti et al., 1998).  Low-expressing lines of 32Dcl3-FUS-ERG 
cells were created (32D-FEP, -FEA, and -FEAB) in addition to high expressing FUS-
ERG (32D-FE1, -FE2, and -FE3).  Two ERG-expressing cell lines, high ERG (32D-M4) 
and low ERG (32D-M12) were created.  All cDNA were tagged with HA.  Granulocytic 
differentiation of 32Dcl3 cells and derivates was induced by G-CSF.        
The amphotropic-packaging cell line Phoenix (Dr. G. P. Noloan, Stanford 
University of Medicine) was maintained in culture in 10% Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco, BR, Gaithersburg, MD), FBS medium, 2mM L-glutamine, 
and 1% penicillin/streptomycin, and grown for 24hr to 80% confluence prior to 
transfection by calcium phosphate-DNA precipitation (ProFection system, Promega, 




 The MIGR1-HA-ERG plasmid was generated as follows:  ERG cDNA was 
amplified by RT-PCR using two sets of primers spanning the BamHI site present in the 
ERG cDNA, and containing at the 3’ end the hemagglutinin (HA) sequence followed by 
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a BglII restriction site.  The RT-PCR products were then phosphorylated, digested with 
BglII and BamHI, and subcloned into previously BglII/HpaI digested retroviral vector 
MIGR1.  The LXSN plasmids containing the HA-tagged wild-type and S256A or S256D 
FUS cDNAs were created as previously described (Perrotti et al., 2000).  Briefly, pSK-
HA S256A FUS (inactive mutant) and pSK-HA S256D FUS (dominant active mutant) 
were XbaI-HindIII digested, blunted, and subcloned into the blunted EcoRI site of the 
LXSP retroviral vector as previously described.  FUS-ERG plasmid was obtained from 
Dr. Ichikawa H. (NCCRI, Tokyo Japan).  The HA-tagged FUS-ERG cDNA was cloned 
into a HindIII site of pLNCX retroviral expression vector as previously described 
(Ichikawa et al., 1999).     
 
Western Blot Analysis 
 
Cells were harvested and lysed:  approximately 106 cells/100 µl of isotonic lysis 
buffer (1% NP-40, 150 mM NaCl, 20nM Hepes at pH 7).  Lysates were clarified by 
centrifugation (12,000g, 15min, 4°C), denatured (10 min, 100oC), after being incubated 
on ice for 30 minutes and subjected to one cycle of freezing-thawing.  Protein lysates 
were denatured in boiling water bath for 10 minutes and subjected to Sodium Dodecyl 
Sufate PolyAcrylamide Gel Electrophoresis (SDS-PAGE).  Proteins in gel were electro-
transferred to nitrocellulose filter and used for Western blot.  Briefly, the filter was 
subjected to washing with TRIS Buffer Saline (TBS) solution (100mM TRIS, 1M NaCl 
at pH 7.6) and blocking with 5% Nestle Carnation Dry Milk.  Primary antibody was 
added followed by secondary antibody.  Primary antibodies used were:  monoclonal anti-
GRB2, monoclonal anti-HA (Covance, Princeton NJ), polyclonal anit-C/EBPα (Santa 
Cruz Biotechnology), polyclonal anti-G-CSFR (Santa Cruz Biotechnology), polyclonal 
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anti-PU.1 (Santa Cruz Biotechnology), monoclonal anti-N-myc 1 (Upstate 
Biotechnology), and polyclonal anti-APP (Cell Signaling Technology).  Secondary 
antibodies used were anti-mouse and anti-rabbit (Amersham Biosciences).  Protein levels 
were detected by chemiluminesence (ECL Western Blotting Detection Agents). 
 
Cytospins    
 
Morphologic differentiation was monitored by May-Grunwald/Giemsa staining of 
cytospin preparations.  At each day of culture in G-CSF-supplemented medium, 
approximately 50-75x103 cells were obtained through centrifugation and re-suspension in 
PBS.  Cells were transferred to Fisher Brand microscope slides via Thermo Shandon 
Cytospin 4 machine.  Stained cells were observed under a Zeiss Axioskop 2 Plus 
microscope for analysis.  
 
Proliferation, Survival, and Differentiation Assays 
 
In order to observe the effect of ERG and FUS-ERG on proliferation and survival, 
infected murine cells were grown in either Interleukin-3 (IL-3)-containing or deprived 
medium for the indicated time.  Percentage of dead and alive cells was monitored by 
Trypan-Blue exclusion test.  The effect of ERG and FUS-ERG on G-CSF-driven myeloid 
proliferation and neutrophilic differentiation was also assessed at the indicated time by 
Trypan-Blue exclusion test. 
 
Immunofluorescence Microscopy 
 5-7.5x104 parental, HA-tagged ERG- and FUS-ERG-expressing 32Dcl3 cells 
were cytospinned on glass slides and fixed for 10 minutes in PBS-containing 3.7% 
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formaldehyde.  Thereafter, cells were washed three times with PBS, permeabilized by 
incubation (10 minutes) in PBS-0.05% Triton X-100 (Sigma), rinsed again with PBS and 
then blocked for 10 minutes in PBS-4% goat serum.  Incubation with the anti-APP 
antibody (1:200 dilution) and with Rhodamine Red-x goat anti-mouse IgG (H+L) (1:300 
dilution).  Molecular probes were carried out at room temperature for 30 minutes.  Slides 
were rinsed three times with PBS, treated with SlowFade Antifade reagent (Molecular 
Probes), and analyzed.   
   
Microarray Analysis 
 
 Microarray analysis was performed to further understand which genes are up or 
downregulated by FUS-ERG, ERG, and FUS.  Total RNA, isolated by acid phenol 
guanidium extraction and isopropenol precipitation, was used to interrogate mouse 
oligonucleotide arrays (The Ohio State University Comprehensive Cancer Center 
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